TY - JOUR
T1 - Immune checkpoint inhibitors in ovarian cancer
T2 - where do we stand?
AU - Leary, Alexandra
AU - Tan, David
AU - Ledermann, Jonathan
N1 - Publisher Copyright:
© The Author(s), 2021.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Numerous retrospective studies have demonstrated that the density of intra-tumoral immune cell infiltration is prognostic in epithelial ovarian cancer (OC). These observations together with reports of programmed death ligand-1 (PD-L1) expression in advanced OC provided the rationale for investigating the benefit of programmed death-1 (PD1) or PD-L1 inhibition in OC. Unfortunately clinical trials to date evaluating PD1/PD-L1 inhibition in patients with relapsed OC have been disappointing. In this review we will discuss early results from single agent PD1/PD-L1 inhibitors and the strategies to enhance benefit from immune-oncology agents in OC, including proposing anti-PD-L1 in combination with other agents (cytotoxics, anti-angiogenics, poly(ADP-ribose) polymerase. (PARP) inhibitors, targeted therapies or other immunotherapies), as well as evaluating these agents earlier in the disease course, or in biomarker selected patients.
AB - Numerous retrospective studies have demonstrated that the density of intra-tumoral immune cell infiltration is prognostic in epithelial ovarian cancer (OC). These observations together with reports of programmed death ligand-1 (PD-L1) expression in advanced OC provided the rationale for investigating the benefit of programmed death-1 (PD1) or PD-L1 inhibition in OC. Unfortunately clinical trials to date evaluating PD1/PD-L1 inhibition in patients with relapsed OC have been disappointing. In this review we will discuss early results from single agent PD1/PD-L1 inhibitors and the strategies to enhance benefit from immune-oncology agents in OC, including proposing anti-PD-L1 in combination with other agents (cytotoxics, anti-angiogenics, poly(ADP-ribose) polymerase. (PARP) inhibitors, targeted therapies or other immunotherapies), as well as evaluating these agents earlier in the disease course, or in biomarker selected patients.
KW - PARP inhibitors
KW - anti-angiogenic
KW - combinations
KW - immune checkpoint inhibitors
KW - ovarian cancer
KW - predictive biomarkers
UR - http://www.scopus.com/inward/record.url?scp=85112707236&partnerID=8YFLogxK
U2 - 10.1177/17588359211039899
DO - 10.1177/17588359211039899
M3 - Review article
AN - SCOPUS:85112707236
SN - 1758-8340
VL - 13
JO - Therapeutic Advances in Medical Oncology
JF - Therapeutic Advances in Medical Oncology
ER -